Ovarian Cancer
Conditions
Interventions
Control Group:Carboplatin+Paclitaxel
Experimental Group:Bevacizumab+Carboplatin+Paclitaxel
Experimental Group A:Dosage according to the combination use of 3D bioprinting technology and dose recommended by the pharmacodynamics
Experimental Group B:Dosage according to the recommended dose of international clinical trial phase III(GOG-0218)
Sponsors
Department of Gynecology and Obstetrics, Renji Hospital Affiliated to Shanghai JiaoTong University School of Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Female over 18 years of age; 2. Patients should have received optimal cytoreductive surgery with residual tumor 1,500/mm3,Platelet count >100,000/mm3, ULN Bilirubin 40ml/min with a normal ejection fraction; 6. Ability andwillingness to give written informed consent.
Exclusion criteria
Exclusion criteria: 1. Non epithelial tumor or borderline tumor; 2. No recurrence patients of postoperative chemotherapy or was performed cytoreductive surgery after chemotherapy; 3. Second kinds of tumors or other tumors received surgical treatment, the treatment and the surgical treatment will affect the treatment of recurrent ovarian cancer, or affect the prognosis of the patients; 4. The patient has received chemotherapy treatment; 5. To carry out palliative surgical treatment only; 6. The combined disease is not suitable for surgery and / or chemotherapy; 7. Has been treated with radiotherapy, experimental therapy, hormone therapy, chemotherapy or biological agents; 8. Any drug known to have a severe allergic history will be used in clinical trials; 9. Past medical history showed that there were serious complications. (1) Severe COPD with hypoxemia; (2) uncontrolled hypertension, cerebrovascular accident/stroke, myocardial infarction, unstable angina,thrombosis,Chronic congestive heart failure or severe arrhythmia needed treatment; (3) severe hepatitis,history of liver disease,nephrotic syndrome,renal insufficiency; (4) History of active ulcer,abdominal fistula,gastrointestinal perforation or abdominal abscess; (5) uncontrolled diabetes; (6) uncontrolled epilepsy which need long-term antiepileptic therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ovarall survival;Progression-Free-Survival;Objective response rate; | — |
Countries
China
Contacts
Public ContactWen Di
Department of Gynecology and Obstetrics, Renji Hospital Affiliated to Shanghai JiaoTong University School of Medicine
Outcome results
None listed